NYU Links ESCO2 Loss to PARP Inhibitor Sensitivity

NYU Langone Health researchers report that loss of the protein ESCO2 makes cancer cells more sensitive to PARP inhibitors through replication stress at a small set of genomic sites, in work published online in Nature Cell Biology on 5 November 2026 and summarised in an NYU Langone release the same day. The study used cancer cell models — not patients — and the authors state that further preclinical and clinical research is needed before these features can guide treatment decisions.

CRISPR screens in breast and small-cell lung cancer models identified ESCO2 as a strong determinant of PARP inhibitor sensitivity. Partial reduction of ESCO2 also increased sensitivity in colorectal, ovarian and lung cancer cells. Critically for the clinical analogy readers may reach for, ESCO2-depleted cells became sensitive while retaining the tested homologous recombination response — so this is not simply another BRCA-style HR-deficiency story.

What the imaging actually showed

ESCO2 helps establish connections that hold newly copied chromosomes together. Using single-molecule imaging methods developed in Eli Rothenberg’s laboratory, the team saw that reducing ESCO2 increased unusual folded DNA structures called G-quadruplexes (G4s), concentrated at a subset of replication sites — especially repetitive pericentromeric regions that help chromosomes segregate correctly.

The protective response depended on PARP1 together with TIMELESS and DDX11 (which can unwind G4s). PARP inhibition disrupted that response in ESCO2-depleted cells: G4s accumulated further, DNA synthesis declined, and damage rose near centromeres. First author Dipika Gupta said the imaging let the team detect subtle replication problems, distinguish the sites involved, and identify the protective response cells relied on. Rothenberg called the pattern a “genomic Achilles’ heel” — a small subset of sites where replication problems have outsized consequences.

The work was a collaboration with Pfizer and was supported in part by NIH grants R01GM134947, R01AI153040, R01CA247773, R01GM139610 and R01ES031658. NYU notes Pfizer/Ionis/Chang Chavkin relationships managed under institutional policy.

Sensitivity maps are not prescriptions

PARP inhibitors already treat some breast and ovarian cancers with BRCA1/BRCA2 mutations that impair homologous recombination. This paper’s claim is different: location of replication stress, not only total damage burden, can shape drug dependence — and ESCO2 points at a non-HR path in cell models. That sits beside other TSN oncology-method stories: King’s College London’s HRDPath work on ovarian cancer, UCL’s TNBC digital twins, and NUS’s DUSP4 CAR-T colorectal study. All are research steps toward better selection, not pharmacy-shelf replacements.

For UK readers, NICE and NHS pathways for PARP inhibitors will not change on a cell-model paper. The useful signal is biomarker science: if ESCO2-linked G4 stress patterns survive in patient-derived models, trialists may eventually test them as enrichment markers. Rothenberg’s group says it is working with clinicians on patient-derived cells toward that end — still upstream of practice. The imaging claim also matters methodologically: being able to distinguish subtypes of replication-associated damage sites is what let the team argue that location, not only quantity, drives dependence on PARP activity.

Lab sensitivity is a lead, not a label on a bottle

This is not a new indication, a new drug, or advice to alter anyone’s therapy. The confirmed result is mechanistic and preclinical: ESCO2 loss sensitises cancer cell models to PARP inhibitors via G4-centred replication stress at vulnerable sites, with an explicit author caveat that further preclinical and clinical research is needed to establish whether these features can guide treatment decisions in patients.

That caveat is doing real work. Biomarker papers often travel faster in headlines than in clinic pathways; the honest reading is a sharper map of where PARP dependence can arise when HR looks intact in the assays the team tested. Watch next for patient-derived validation, whether Pfizer’s collaboration yields a companion assay story, and whether any trial protocol cites ESCO2/G4 patterns as stratification tools. Until then, PARP inhibitors remain the clinical class they were yesterday — with a clearer map of one non-HR sensitivity route in the dish.

Sources

• Advanced imaging uncovers a genomic Achilles’ heel that makes cancer cells vulnerable to treatment (NYU Langone, 5 November 2026)
• Positional replication fork instability drives PARP inhibitor cytotoxicity (Gupta, Ding, Zhang et al., Nature Cell Biology, published online 5 November 2026)

Related stories

• KCL AI Spots DNA-Repair Defect in Ovarian Cancer From Routine Slides
• UCL Digital Twins Suggest Extra Drugs for Hard-to-Treat Breast Cancer
• Protein DUSP4 Boosts CAR-T Cells Against Colorectal Cancer in Mice